Market Overview

Liquid biopsy provides cancer diagnostic and monitoring capabilities through its minimally invasive tissue biopsy replacement technology. Blood tests enable real-time ctDNA and CTCs and exosomes analysis through which healthcare providers detect cancer at its early stages and track treatment response and detect cancer recurrence. The combination of rising interest in personalized medicine and better genomic profiling and next-generation sequencing (NGS) technologies drives the increasing use of liquid biopsy within oncology practice. Precision medicine is receiving critical support from liquid biopsy technology because healthcare providers actively seek faster and safer diagnostic methods that are also cost-effective.

Key Players

F HoffmannLa Roche Ltd, Qiagen NV, BioRad Laboratories Inc, Thermo Fisher Scientific Inc, Illumina Inc, Menarini Silicon Biosystems, Guardant Health Inc, Myriad Genetics Inc, Biocept Inc, Trovagene Inc, Genomic Health Inc, Adaptive Biotechnologies, Cynvenio Biosystems Inc, Exosome Diagnostics Inc, BioTechne Corporation, Natera Inc, ANGLE plc, Epic Sciences Inc, Personal Genome Diagnostics Inc, Guardant Health Inc

Sample link   -    https://www.trendbridgeinsights.com/industry-report/liquid-biopsy-market

Market segmentation:

Product Type

·       Circulating Tumor Cells CTCs

·       Circulating Tumor DNA ctDNA

·       Exosomes

·       Other Biomarkers

Sample Type

·       Blood

·       Urine

·       Saliva

·       Cerebrospinal Fluid CSF

Application

·       Oncology

·       Noninvasive Prenatal Testing NIPT

·       Transplant Diagnostics

·       Other Applications

End User

·       Hospitals and Clinics

·       Diagnostic Centers

·       Research and Academic Institutes

·       Other End Users

Technology

·       PCR Polymerase Chain Reaction

·       NGS NextGeneration Sequencing

·       Microarray

·       Other Technologies

Mega Trend Connect:

This report offers deep insights into how mega trends such as digitalization, precision medicine, data-driven care delivery, and regulatory evolution are transforming medical devices. It further examines the impact of advanced technologies, platform-based models, automation, and interoperability across products and services within this segment. The report assesses regulatory complexity, adoption readiness, cost pressures, and ecosystem maturity shaping global market development.

Global Trade Outlook:

Global trade in medical devices is increasingly shaped by regulatory stringency, localization mandates, data sovereignty requirements, and public health policy priorities. Cross-border scalability is constrained by approval timelines, compliance variation, and infrastructure readiness, driving regionalized production, partnerships, and delivery models. Market access and competitiveness now depend on regulatory agility, localized execution, and compliance-by-design strategies.

Region Analysis :

North America leads the liquid biopsy market due to strong precision medicine adoption, advanced healthcare systems, and major U.S. investments in oncology diagnostics. Europe follows with rising cancer incidence and expanding molecular testing capacity. Asia-Pacific grows fastest as China, India, Japan, and South Korea strengthen early detection programs. Latin America and MEA show steady adoption driven by improving healthcare access.

Recent development :

In March 2025, Guardant Health introduced its advanced liquid biopsy test platform to provide better early cancer detection sensitivity for various tumor types thus broadening its clinical applications.

FAQ:

1 .  What is the Forecasted market size & CAGR of the Liquid Biopsy Market ?

The Liquid Biopsy Market reached USD 4.2 billion in 2024, and analysts predict it will expand at a 20-25% CAGR to touch USD 26-28 billion by 2031.

2. Who are the leading manufacturers and suppliers in the Liquid Biopsy Market ?

F HoffmannLa Roche Ltd, Qiagen NV, BioRad Laboratories Inc, Thermo Fisher Scientific Inc, Illumina Inc, Menarini Silicon Biosystems, Guardant Health Inc, Myriad Genetics Inc

3. What are the upcoming trends of Liquid Biopsy Market in the globe?

Rise of Multi-Analyte Testing Platforms: The development of next-generation liquid biopsy solutions now includes ctDNA and RNA and exosomes and CTCs for complete tumor profiling which enhances diagnostic precision.

4. Which is the largest regional market for Liquid Biopsy Market ?

North America leads the liquid biopsy market because it has superior healthcare infrastructure and strong adoption of precision medicine and active research activities.

About US:

Company information

(TrendBridge Insights is a premier global market research and consulting firm that provides comprehensive market intelligence, strategic insights, and data-driven solutions to businesses worldwide. With over 15 years of expertise across diverse industries, we help organizations make informed decisions that drive growth and competitive advantage.)

Contact US

Ganesh

Mail — info@trendbridgeinsights.com

Website Link-https://trendbridgeinsights.com/

Linkedin Page- https://www.linkedin.com/company/trend-bridge-insights/

Reference Links :

https://www.trendbridgeinsights.com/industry-report/colorectal-cancer-screening-market

https://www.trendbridgeinsights.com/industry-report/companion-diagnostics-market

https://www.trendbridgeinsights.com/industry-report/contact-lenses-market

https://www.trendbridgeinsights.com/industry-report/c-reactive-protein-testing-market

https://www.trendbridgeinsights.com/industry-report/demineralized-bone-matrix-dbm-market

https://www.trendbridgeinsights.com/industry-report/dental-bone-graft-substitutes-market